Charles River Launches Viral Vector Reference Materials To Streamline the Transition To GMP
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (NYSE:CRL) has launched a new portfolio of reference materials for AAV and LVV, aimed at streamlining Cell and Gene Therapy (CGT) research and development towards GMP quality. This includes six AAV serotypes and five LVV products, enhancing their CDMO offerings and supporting the transition from discovery to commercial stages in CGT.
May 02, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River's launch of AAV and LVV reference materials represents a significant enhancement to its CGT CDMO offerings, potentially accelerating the transition from research to commercialization in gene therapies.
The introduction of these reference materials directly impacts Charles River's position in the CGT market by potentially attracting more clients and partnerships, due to the improved efficiency and quality of CGT development processes. This could lead to increased revenue from their CDMO services.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100